Vivek Ramaswamy

Vivek graduated from Harvard College in 2007 with top honors (summa cum laude) and membership in the prestigious Phi Beta Kappa society, having completed a degree in biology. He wrote a senior thesis exploring the ethical issues involved in creating human-animal chimeras, with guidance from his mentor Professor Douglas Melton. His thesis received the Bowdoin Prize for Natural Sciences and was published in 2007 by The New York Times and The Boston Globe.

In the same year, Vivek co-founded Campus Venture Network, a tech firm that assisted university entrepreneurs with networking resources and software. The company was acquired by the Ewing Marion Kauffman Foundation in 2009.

From 2007 to 2014, Vivek worked as a partner at hedge fund QVT Financial, where he managed the firm's biotech portfolio. During this time, he also attended Yale Law School (from 2010 to 2013).

Vivek went on to become the Founder & CEO of Roivant Sciences until 2021, a pharmaceutical company worth billions of dollars that uses technology to revolutionize drug development. Roivant has established multiple subsidiary companies in the biotech and healthcare tech fields, many of which are publicly listed.

In 2020, Vivek joined the Ohio COVID-19 Response Team and is also a bestselling author for The New York Times. He sits on the boards of The Philanthropy Roundtable, FreOpp, and The Foundation for Research on Equal Opportunity.